Skip to main content
. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887

Figure 3.

Figure 3

Targeting XBP-1s abrogates human moDC production of IL-1β, TGFβ, and diminishes alloresponder Th17 differentiation. (A–C) Supernatant concentrations of IL-1β, TGFβ, or IL-6 from LPS-stimulated moDCs exposed to B-I09 or DMSO after 24 h of culture are shown. Replicate means from 5 (IL-1 β), 3 (TGFβ), and 4 (IL-6) independent experiments are shown, paired t-test. (D–H) T cells were cultured with B-I09 or DMSO pre-treated moDCs (moDC:T cell ratio of 1:30), and additional B-I09 (20 μM) or DMSO (0.1%) was added once on day 0. pSTAT3+ CD4+ T cells were analyzed at day +5 by flow cytometry (D) and representative histograms are shown (E). Means from 3 independent experiments are shown, paired t-test. (F) Total STAT3 was measured in T cells from co-cultures of DCs and T cells treated with B-I09 or DMSO. Means from 3 experiments are shown. In similarly treated co-cultures, the supernatant concentration of IL-17 was quantified (G) and Th17 (CD4+, CCR6+, IL-17A+) differentiation was evaluated by flow cytometry (H,I). Replicate means from 3 (IL-17 ELISA) and 4 (Th17) independent experiments, paired t-test. (I) Representative contour plots are shown.